Skip to main content
. 2024 Sep 20;15(19):3543–3562. doi: 10.1021/acschemneuro.4c00453

Figure 1.

Figure 1

Overview of Aducanumab::Aβ2–7 crystallographic structure with HC’s missing residues modeled. (A) Crystallographic structure of Aducanumab::Aβ2–7 represented in the cartoon with HC, LC, and Aβ2–7 colored in red, blue, and gray. (B) Portion subjected to molecular dynamics simulations corresponding to the variable fragment heavy chain (VH) and variable fragment light chain (VL) bound to Aβ2–7. (C) Illustration of the main contacts on the Aducanumab::Aβ2–7 surface.